Back to search

Article

Pulsed priming with the FAK inhibitor narmafotinib enhances both gemcitabine/Abraxane and FOLFIRINOX chemotherapy response in pancreatic cancer

2026-07-23

Abstract excerpt

<h4>ABSTRACT</h4> <h4>Background</h4> Pancreatic ductal adenocarcinoma (PDAC) is a particularly lethal malignancy with few treatment options available. Extensive remodelling of extracellular matrix (ECM) generates a highly fibrotic tumour landscape, which impairs therapeutic response. <h4>Objective</h4> We investigated whether stromal priming via the highly specific Focal Adhesion Kinase (FAK) inhibitor narmaf...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
cf9d1702-eda9-5061-a22d-728ae53e3e4f
DOI
10.64898/2026.07.23.740234
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Pulsed priming with the FAK inhibitor narmafotinib enhances both gemcitabine/Abraxane and FOLFIRINOX chemotherapy response in pancreatic cancerDOI 10.64898/2026.07.23.740234
Select a neighboring publication to make it the new centre.